Summary of the HIV virus inhibitory effect and clinical efficacy of Biken Pronol Tablets (Bituvi)

Biktarvy is a fixed-dose compound oral preparation, consisting of three anti-HIV drugs: Bictegra vir), propituxivir fumarate (Emtricitabine) and tenofovir alafenamide fumarate (Tenofovir alafenamide, TAF). Among them, bictasvir is an integrase inhibitor (INSTI) that blocks HIV DNA is integrated into the host genome to achieve efficient inhibition of viral replication; protuxivir and tenofovir TAF are nucleoside reverse transcriptase inhibitors (NRTI), which further inhibit viral proliferation by interfering with the HIV reverse transcription process. The three-drug combination forms a high-efficiency, once-a-day, low-risk treatment regimen that is suitable for HIV infection patients who are newly treated and on stable treatment.

Clinical studies have shown that Biktarvy can significantly suppress HIV viral load in a short period of time. In treatment-naïve HIV patients, after oral administration of Biktarvy for 24 weeks, approximately 90% or more of the patient's plasmaHIV RNAcan be reduced to undetectable levels (<50copies/mL) and maintained for 48 weeks or even longer. In the long-term efficacy evaluation, Biktarvy showed rapid onset of effect, stable viral suppression, and low recurrence rate. For patients who have failed to use other antiviral regimens in the past, Biktarvy can also achieve suppression of viral replication and reduce the emergence of drug-resistant strains through the advantage of high genetic barrier.

Biktarvynot only performs well in virology, but also improves the immune function and quality of life of HIV patients. Through viral suppression, CD4+ T lymphocyte count can be significantly increased, reducing the risk of opportunistic infections. In terms of patient-reported quality of life, fixed-dose, once-daily dosing significantly improved medication compliance and reduced the risk of missed doses, while reducing drug-related side effects such as nephrotoxicity, bone density loss, and gastrointestinal discomfort. These characteristics make Biktarvy one of the globally recommended first-line HIV treatment options, especially suitable for chronic patients who require long-term maintenance of suppression.HIVinfected patients.

Biktarvyhas a high genetic barrier. Biktarvy remains active against known integrase resistance mutations. At the same time, the NRTI component stabilizes blood concentrations and effectively prevents the formation of drug-resistant strains. Long-term follow-up showed that most patients did not develop significant drug resistance within 2–5 years. In addition, Biktarvy has little impact on renal function and bone metabolism, and is suitable for long-term use by most HIV patients. In terms of clinical management, it is recommended to regularly monitor HIV RNA, CD4+ cell count and liver and kidney function to ensure sustained and stable efficacy, and adjust medication or combined supportive treatment according to individual conditions.

In special groups, such as elderly patients, patients with chronic kidney disease or HIV patients undergoing concomitant drug treatment, Biktarvy also shows good tolerability and safety. Its low drug interaction profile allows patients to take cardiovascular medications or other chronic disease medications concurrently without the need for frequent dose adjustments. In addition, Biktarvy’s simple medication regimen reduces psychological burden, improves patients’ long-term medication compliance, and provides a more convenient and reliable option for chronic HIV management.

In general, Biktarvy tablets (Biktarvy) have the advantages of high viral suppression, sustained and stable efficacy, low risk of drug resistance and good tolerability in the treatment of HIV infection. Its fixed-dose, once-daily administration improves compliance and reduces the burden of medication in daily life. Biktarvynot only can quickly reduce viral load and restore immune function, but can also maintain plasmaHIV RNA in an undetectable state for a long time, thereby reducing the risk of opportunistic infections and complications. Biktarvyis recommended in global guidelines as a first-line or conversion treatment and is an important component of modern HIV treatment.

Reference materials:https://www.drugs.com/